| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anethole — Anethole is a naturally occurring aromatic phenylpropene and volatile essential-oil constituent best represented by trans-anethole, the dominant anise-like compound in anise, star anise, fennel, and related botanicals. It is formally a small-molecule natural product / flavoring-agent phytochemical rather than an approved oncology drug. Standard abbreviations include ANE, t-ANE, and tAT for trans-anethole. In cancer research it is best classified as a preclinical multi-pathway chemosensitizing phytochemical with stronger evidence for apoptosis, cell-cycle arrest, NF-κB/PI3K-AKT/STAT3 modulation, and context-dependent oxidative-stress effects than for direct clinical use. Primary mechanisms (ranked):
Bioavailability / PK relevance: Anethole is lipophilic and orally absorbable, with human metabolic studies showing dose-dependent disposition and major urinary detoxication products such as 4-methoxyhippuric acid. Translation is constrained by rapid metabolism, flavor-level safety limits, and the fact that many anticancer experiments use concentrations unlikely to be achieved safely through dietary exposure. In-vitro vs systemic exposure relevance: Most anticancer effects are concentration-driven and commonly occur in the tens to hundreds of micromolar range. These levels likely exceed normal dietary or flavoring exposure and should be treated as pharmacologic experimental exposure rather than food-use exposure. Clinical evidence status: Preclinical. There is no established human oncology indication for anethole and no convincing registered cancer trial program for anethole as an anticancer therapy. Evidence is mainly cell-culture, limited animal xenograft, and combination/sensitization studies. Anethole Cancer Mechanism Table
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| AChE is an enzyme that rapidly hydrolyzes the neurotransmitter acetylcholine into choline and acetate, terminating cholinergic signals. - In some cancers, studies have reported reduced AChE activity, which may contribute to an accumulation of acetylcholine. - Lower levels or loss of AChE expression/activity have been associated with more aggressive tumor behavior and poor prognosis, possibly due to unchecked cholinergic signaling. For AD (Alzheimer's), AChE inhibitors are used, to allow ACh, and ChAT to increase along with acetyl-CoA -Natural AChE inhibitors: Ferulic Acid, Caffeic Acid, Rosmarinic Acid, Sage -AChE inhibitors only temporarily relieve some of the disease’s cognitive symptoms and do not stop the patient’s cognitive loss -adverse effects such as disorientation, falls, dizziness, and fatigue may occur with these medications and should be used only as recommended - Natural AChE inhibitors paper |
| 6400- | ANE, | FEO, | A comprehensive review of the neurological effects of anethole |
| - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:402 Target#:1329 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid